Jump to content

Bernhard Landwehrmeyer

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Pippin2k (talk | contribs) at 17:34, 2 May 2022. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.



Georg Bernhard Landwehrmeyer
FRCP
Born
Freiburg, Germany
NationalityGerman
CitizenshipGermany
Alma materUniversity of Freiburg
Queen's University of Belfast
Harvard Medical School
Kantonsspital St. Gallen
Known forResearch into neurodegeneration, particularly Huntington disease
Scientific career
FieldsNeuroscience
InstitutionsUKU
Thesis (1990)
Doctoral advisorProf. Dr. R. Jung
Websitewww.uniklinik-ulm.de/neurologie/sprechstunden-ambulanzen/morbus-huntington.html

Georg Bernhard Landwehrmeyer, MD, PhD, FRCP is a German neurologist and neuroscientist in the field of neurodegeneration primarily focusing on Huntington's disease.[1] Prof. Landwehrmeyer is a full professor of neurology at Ulm University Hospital, department of neurology. He was one of the founders of the the European Huntington’s Disease Network (EHDN) in 2004 and was chairman of its Executive Committee until 2014.[1]

Education and Career

Bernhard Landwehrmeyer received his MD degree and Doctoral Degree from the Albert Ludwigs University of Freiburg, Germany, where he also completed a residency in neurology, research training in neuropathology and molecular pharmacology, and a residency in neurology and psychiatry.[1][2] Prof. Landwehrmeyer studied at the Royal Victoria Hospital, Belfast and Kantonsspital St. Gallen, Basel. He was a post-Doc from 1993 to 1995 at Massachusetts General Hospital, Harvard Medical School. During 1995–1999, he was a staff member at Albert Ludwigs University of Freiburg, Department of Neurology & Psychiatry. In 1999, he received his Board certification in Neurology and has been a full professor since 2000.[3] He served as principal investigator in numerous HD clinical trials[4][5][6] and observational studies[7][8] and is the principal investigator of the CHDI-sponsored Enroll-HD study.[3]

Research

Landwehrmeyer started working on Huntington's Disease (HD) in 1993 when he started a postdoc at Massachusetts General Hospital (MGH) with Anne B. Young, then Chief of Neurology, a couple of months before the HD gene and the HD expansion mutation was discovered. He went to Venezuela with Anne and Nancy Wexler several times, and was alerted to stimulating HD field studies aside from work at the bench.

In 2000 he was appointed full Professor of Neurology, ‘Clinical Neurobiology,’ at the University of Ulm and was given the opportunity to organize (together with Albert Ludolph, the chairperson of the Department of Neurology at the University of Ulm, who initiated the work) the first large (>500 participants), long-term (3-year randomized clinical trial, followed by a blinded extension) multicenter European phase III HD trial. This collaboration led to forming the European HD Network (EHDN) in 2003-2004, funded by CHDI Foundation, a philanthropic US-American organization. He is the founding Chair of the Executive Committee of EHDN and served in this capacity in 2004–2014. He continues to serve as leader of the EHDN project at the University of Ulm.

The large prospective observational cohort study REGISTRY, conducted by EHDN, recruiting more than 15,000 participants, merged with the cohort study of the Huntington Study Group (HSG) to form Enroll-HD in 2011. Prof. Landwehrmeyer serves as the Principal Investigator (PI) of Enroll-HD, a worldwide platform to facilitate HD research and to conduct prospective, observational HD cohort studies for HD families.

He is the recipient of research awards for his work that focuses on neurodegenerative diseases, such as HD and Parkinson Disease, ranging from basic science bench work, translational studies to randomized controlled trials (RCTs), care improvement projects and community work to raise awareness for HD. He was involved in almost all RCTs in HD conducted in Europe since 1999, often serving as coordinating PI or national lead investigator. He contributed to Track-HD and to 26 phase I-III clinical trials, primarily in HD, including a first-in-man intrathecal application of antisense oligonucleotides ASO to silence huntingtin gene expression evaluating the safety, tolerability, and efficacy of intrathecally administered agents as well as non-pharmacological interventions, studying the impact of physical activity and exercise in people with HD.

Prof. Landwehrmeyer directs the HD Center Ulm, where a multi-disciplinary team takes care of over 700 with HD in an out-patient setting where more than 600 agreed to participate in Enroll-HD. This multi-disciplinary center provides genetic counselling, clinical in- and out-patient services as well as rehabilitation for HD affected families along with basic and translational science. In addition, the HD Center South (in Taufkirchen/Vils) offers 19 in-patient beds dedicated to HD in the setting of a psychiatric hospital and 20-25 beds for in-patient rehab at Ulm.

Prof. Landwehrmeyer’s publications appeared in numerous prestigious journals[9], including The New England Journal of Medicine[10], JAMA[11][12][13], Cell[14][15], Molecular Cell[16][17], Nature Genetics[18], Nature Neuroscience[19], EMBO Molecular Medicine[20], Lancet Neurology[21][22][23][24][25][26], Annals of Neurology[27][28][29][30][31], Brain[32][33][34][35], Neurology[36][37][38][39][40][41][42][43][44][45], Movement Disorders[46][47][48][49][50][51][52][53][54], NeuroImage[55], Journal of Cerebral Blood Flow & Metabolism[56], Scientific Reports[57], and others. Other topics on which he published include frontotemporal lobar degeneration (FTD)[58][59][60][61][62], amyotrophic lateral sclerosis[63][64] (ALS), Parkinsonian disorders (including progressive supranuclear palsy and multiple system atrophy)[65] and pain[66][67].

Prof. Landwehrmeyer is a Fellow of the Royal College of Physicians and a member of several learned medical societies, including the Society for Neuroscience, American Academy of Neurology, American Society for Experimental Neurotherapeutics, European Federation of Neurological Societies, German Society for Neurogenetics, European Huntington Disease Network, and Movement Disorders Society.

As of April 2022, Landwehrmeyer had authored over 300 publications, with over 15,000 citations for his research.[9]

Research awards

Personal life

Prof. Landwehrmeyer currently lives in Ulm, Germany. His father, Richard Landwehrmeyer [de], was a German librarian. From 1972 to 1987 he headed the University Library of Tübingen[74] and from 1987 to 1995 the State Library of Berlin as Director General.

References

  1. ^ a b c Landwehrmeyer, G Bernhard (2012). "Interview: Following a standard of care for Huntington's disease". Neurodegener Dis Manag. 2 (2): 159–63. doi:10.2217/nmt.12.3.
  2. ^ Deeprose, Catherine (2 July 2021). "Taking Stock: Interview with G. Bernhard Landwehrmeyer" (PDF). EHDN News. No. 43. Retrieved 30 April 2022.
  3. ^ a b "Executive Committee - Public Documents". European Huntington’s Disease Network. European Huntington’s Disease Network. Retrieved 30 April 2022.
  4. ^ "An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196 (PADDINGTON)". ClinicalTrials.gov. United States National Library of Medicine. 24 November 2015. Retrieved 1 May 2022. ... Principal Investigator: Bernhard G Landwehrmeyer, MD, PhD European Huntington's Disease Network ...'
  5. ^ "Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (PEARL-HD)". ClinicalTrials.gov. United States National Library of Medicine. 31 May 2016. Retrieved 1 May 2022. ... Principal Investigator: Bernhard Landwehrmeyer, MD, PhD Ulm University Hospital ...'
  6. ^ "Effects of Pregabalin on Mechanical Hyperalgesia". ClinicalTrials.gov. United States National Library of Medicine. 4 April 2007. Retrieved 1 May 2022.
  7. ^ "REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)". ClinicalTrials.gov. United States National Library of Medicine. 14 September 2017. Retrieved 1 May 2022. ... Principal Investigator: Bernhard Landwehrmeyer, Professor University Hospital of Ulm / Dept. of Neurology ...'
  8. ^ "Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort". ClinicalTrials.gov. United States National Library of Medicine. 29 March 2022. Retrieved 1 May 2022. ... Principal Investigator: Bernhard G Landwehrmeyer, MD, PhD University of Ulm ...'
  9. ^ a b "Georg Bernhard Landwehrmeyer - Web of Science Citations". Publons: Track more of your research impact.
  10. ^ Tabrizi, Sarah J; Leavitt, Blair R; Landwehrmeyer, G Bernhard (2019). "Targeting Huntingtin Expression in Patients with Huntington's Disease". N Engl J Med 2019. 680 (24): 2307–2316. doi:10.1056/NEJMoa1900907. PMID 31059641. S2CID 146811503.
  11. ^ Langbehn, Douglas R; Stout, Julie C; Gregory, Sarah; Mills, James A; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A C; Long, Jeffrey D; Owen, Gail; Johnson, Hans J; Borowsky, Beth; Craufurd, David; Reilmann, Ralf; Landwehrmeyer, G Bernhard (2019). "Association of CAG Repeats With Long-term Progression in Huntington Disease". JAMA Neurol. 76 (11): 1375–1385. doi:10.1001/jamaneurol.2019.2368. PMC 6692683. PMID 31403680.
  12. ^ Long, Jeffrey D; Mills, James A; Leavitt, Blair R; Durr, Alexandra; Roos, Raymund A; Stout, Julie C; Reilmann, Ralf; Landwehrmeyer, Bernhard (2017). "Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis". JAMA Neurol. 74 (11): 1352–1360. doi:10.1001/jamaneurol.2017.2107. PMC 5710578. PMID 28975278.
  13. ^ HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network (2013). "A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease". JAMA Neurol. 70 (1): 25–33. doi:10.1001/2013.jamaneurol.382. PMID 23108692. ... *The authors for the HORIZON Investigators of the Huntington Study Group and European Huntington's Disease Network are as follows: <…> Georg B. Landwehrmeyer ...
  14. ^ Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2019). "CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset". Cell. 178 (4): 887–900. doi:10.1016/j.cell.2019.06.036. PMC 6700281. PMID 31398342. ... Consortia <…> Group 5: Michael Orth and G. Bernhard Landwehrmeyer on behalf of the European Huntington's Disease Network (EHDN) Registry investigators; Jane S. Paulsen on behalf of the Huntington Study Group (HSG) PREDICT-HD investigators ...
  15. ^ Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015). "Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease". Cell. 162 (3): 516–526. doi:10.1016/j.cell.2015.07.003. PMC 4524551. PMID 26232222.
  16. ^ Goehler, Heike; Lalowski, Maciej; Stelzl, Ulrich; Waelter, Stephanie; Stroedicke, Martin; Worm, Uwe; Droege, Anja; Lindenberg, Katrin S; Knoblich, Maria; Haenig, Christian; Herbst, Martin; Suopanki, Jaana; Scherzinger, Eberhard; Abraham, Claudia; Bauer, Bianca; Hasenbank, Renate; Fritzsche, Anja; Ludewig, Andreas H; Buessow, Konrad; Coleman, Sarah H; Gutekunst, Claire-Anne; Landwehrmeyer, G Bernhard (2004). "A Protein Interaction Network Links GIT1, an Enhancer of Huntingtin Aggregation, to Huntington's Disease". Molecular Cell. 15 (6): 853–865. doi:10.1016/j.molcel.2004.09.016. PMID 15383276.
  17. ^ Lunkes, Astrid; Lindenberg, Katrin S; Ben-Haı̈em, Léa; Weber, Chantal; Devys, Didier; Landwehrmeyer, G Bernhard; Mandel, Jean-Louis; Trottier, Yvon (2002). "Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions". Molecular Cell. 10 (2): 259–269. doi:10.1016/S1097-2765(02)00602-0. PMID 12191472.
  18. ^ van Rheenen, Wouter; Shatunov, Aleksey; Dekker, Annelot M (2016). "Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis". Nat Genet. 48 (9): 1043–1048. doi:10.1038/ng.3622. PMC 5556360. PMID 27455348. ...  Department of Neurology, Ulm University, Ulm, Germany: Bernhard Landwehrmeyer, Albert C Ludolph, Jochen H Weishaupt & Peter M Andersen ...'
  19. ^ McAllister, Branduff; Donaldson, Jasmine; Binda, Caroline S (2022). "Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset". Nat Neurosci. 25 (4): 446–457. doi:10.1038/s41593-022-01033-5. PMC 8986535. PMID 35379994. ...  Department of Neurology, Ulm University, Ulm, Germany: Bernhard Landwehrmeyer ...'
  20. ^ Lehmer, Carina; Oeckl, Patrick; Weishaupt, Jochen H; Volk, Alexander E; Diehl-Schmid, Janine; Schroeter, Matthias L; Lauer, Martin; Kornhuber, Johannes; Levin, Johannes; Fassbender, Klaus; Landwehrmeyer, Bernhard (2017). "Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS/FTD". EMBO Mol Med. 9 (7): 859–868. doi:10.15252/emmm.201607486. PMC 5494528. PMID 28408402.
  21. ^ Reilmann, Ralf; McGarry, Andrew; Grachev, Igor D; Savola, Juha-Matti; Borowsky, Beth; Eyal, Eli; Gross, Nicholas; Langbehn, Douglas; Schubert, Robin; Wickenberg, Anna Teige; Papapetropoulos, Spyros; Hayden, Michael; Squitieri, Ferdinando; Kieburtz, Karl; Landwehrmeyer, G Bernhard (2019). "Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study". Lancet Neurol. 18 (2): 165–176. doi:10.1016/S1474-4422(18)30391-0. PMID 30563778. S2CID 54588998.
  22. ^ Fusilli, Caterina; Migliore, Simone; Mazza, Tommaso; Consoli, Federica; De Luca, Alessandro; Barbagallo, Gaetano; Ciammola, Andrea; Gatto, Emilia Mabel; Cesarini, Martin; Etcheverry, Jose Luis; Parisi, Virginia; Al-Oraimi, Musallam; Al-Harrasi, Salma; Al-Salmi, Qasem; Marano, Massimo; Vonsattel, Jean-Paul Gerard; Sabatini, Umberto; Landwehrmeyer, Georg Bernhard; Squitieri, Ferdinando (2018). "Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis". Lancet Neurol. 17 (11): 986–993. doi:10.1016/S1474-4422(18)30294-1. PMID 30243861. S2CID 52336127.
  23. ^ Moss, Davina J Hensman; Pardiñas, Antonio F; Langbehn, Douglas; Lo, Kitty; Leavitt, Blair R; Roos, Raymund; Durr, Alexandra; Mead, Simon; TRACK-HD investigators; REGISTRY investigators (2017). "Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study". Lancet Neurol. 16 (9): 701–711. doi:10.1016/S1474-4422(17)30161-8. PMID 28642124. S2CID 588163.
  24. ^ Tabrizi, Sarah J; Scahill, Rachael I; Owen, Gail; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A; Borowsky, Beth; Landwehrmeyer, Bernhard (2013). "Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data". Lancet Neurol. 12 (7): 673–49. doi:10.1016/S1474-4422(13)70088-7. PMID 23664844. S2CID 12204298.
  25. ^ Yebenes, Justo Garcia de; Landwehrmeyer, Bernhard; Squitieri, Ferdinando (2011). "Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial". Lancet Neurol. 10 (12): 1049–57. doi:10.1016/S1474-4422(11)70233-2. PMID 22071279. S2CID 39984761.
  26. ^ Tabrizi, Sarah J; Scahill, Rachael I Alexandra Durr; Roos, Raymund Ac; Leavitt, Blair R; Jones, Rebecca; Landwehrmeyer, G Bernhard (2011). "Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis". Lancet Neurol. 10 (1): 31–42. doi:10.1016/S1474-4422(10)70276-3. PMID 21130037. S2CID 2602096.
  27. ^ Landwehrmeyer, G. Bernhard; McNeil, Sandra M.; Dure, Leon S. IV (1995). "Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals". Ann Neurol. 37 (2): 218–30. doi:10.1002/ana.410370213. PMID 7847863. S2CID 40930776.
  28. ^ Schmidt, Thorsten; Lindenberg, Katrin S; Krebs, Antje; Schöls, Ludger; Laccone, Franco; Herms, Jochen; Rechsteiner, Martin; Riess, Olaf; Landwehrmeyer, G. Bernhard (2002). "Protein surveillance machinery in brains with spinocerebellar ataxia type 3: Redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions". Ann Neurol. 51 (3): 302–310. doi:10.1002/ana.10101. PMID 11891825. S2CID 251900.
  29. ^ Gizatullina, Zemfira Z; Lindenberg, Katrin S; Harjes, Phoebe; Chen, Ying; Kosinski, Christoph M; Landwehrmeyer, Bernhard G (2006). "Low stability of huntington muscle Mitochondria against Ca2+ in R6/2 mice". Ann Neurol. 59 (2): 407–411. doi:10.1002/ana.20754. PMID 16437579. S2CID 29281956.
  30. ^ Landwehrmeyer, G. Bernhard; Dubois, Bruno; de Yébenes, Justo Garcia (2007). "Riluzole in Huntington's disease: a 3-year, randomized controlled study". Ann Neurol. 62 (3): 161–272. doi:10.1002/ana.21181. PMID 17702031. S2CID 23715098.
  31. ^ van der Burg, Jorien M M; Gardiner, Sarah L; Ludolph, Albert C; Landwehrmeyer, G Bernhard (2017). "Body weight is a robust predictor of clinical progression in Huntington disease". Ann Neurol. 82 (3): 479–483. doi:10.1002/ana.25007. PMID 28779551. S2CID 20730952.
  32. ^ McColgan, Peter; Seunarine, Kiran K; Razi, Adeel; Cole, James H; Gregory, Sarah; Durr, Alexandra; Roos, Raymund A C; Stout, Julie C; Landwehrmeyer, Bernhard (2015). "Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease". Brain. 138 (11): 3327–3344. doi:10.1093/brain/awv259. PMC 4620513. PMID 26384928.
  33. ^ Brown, Richard G; Lacomblez, Lucette; Landwehrmeyer, Bernard G (2010). "Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy". Brain. 133 (8): 2382–2393. doi:10.1093/brain/awq158. PMID 20576697.
  34. ^ Wolf, Robert Christian; Vasic, Nenad; Schönfeldt-Lecuona, Carlos; Landwehrmeyer, G. Bernhard; Ecker, Daniel (2007). "Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI". Brain. 130 (11): 2845–2857. doi:10.1093/brain/awm210. PMID 17855375.
  35. ^ Behrens, P F; Franz, P; Woodman, B; Lindenberg, K S; Landwehrmeyer, G B (2002). "Impaired glutamate transport and glutamate–glutamine cycling: downstream effects of the Huntington mutation". Brain. 125 (8): 1908–1922. doi:10.1093/brain/awf180. PMID 12135980.
  36. ^ McAllister, Branduff; Gusella, James F; Landwehrmeyer, G Bernhard (2021). "Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease". Neurology. 96 (19): e2395–e2406. doi:10.1212/WNL.0000000000011893. PMC 8166441. PMID 33766994.
  37. ^ Aziz, N Ahmad; van der Burg, Jorien M M; Tabrizi, Sarah J; Landwehrmeyer, G Bernhard (2018). "Overlap between age-at-onset and disease-progression determinants in Huntington disease". Neurology. 90 (24): e2099–e2106. doi:10.1212/WNL.0000000000005690. PMC 5996832. PMID 29743208.
  38. ^ Steinacker, Petra; Semler, Elisa; Anderl-Straub, Sarah; Diehl-Schmid, Janine; Schroeter, Matthias L; Uttner, Ingo; Foerstl, Hans; Landwehrmeyer, Bernhard (2017). "Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias". Neurology. 88 (10): 961–969. doi:10.1212/WNL.0000000000003688. PMID 28179468. S2CID 46394571.
  39. ^ Squitieri, Ferdinando; Landwehrmeyer, Bernhard; Reilmann, Ralf (2013). "One-year safety and tolerability profile of pridopidine in patients with Huntington disease". Neurology. 80 (12): 1086–1094. doi:10.1212/WNL.0b013e3182886965. PMID 23446684. S2CID 38499563.
  40. ^ Lee, J.-M.; Ramos, E M; Lee, J.-H. (2012). "CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion". Neurology. 78 (10): 690–695. doi:10.1212/WNL.0b013e318249f683. PMC 3306163. PMID 22323755.
  41. ^ Bechtel, N; Scahill, R I; Rosas, H D (2010). "Tapping linked to function and structure in premanifest and symptomatic Huntington disease". Neurology. 75 (24): 2150–2160. doi:10.1212/WNL.0b013e3182020123. PMC 3013584. PMID 21068430.
  42. ^ Aziz, N A; Jurgens, C K; Landwehrmeyer, G B (2009). "Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease". Neurology. 73 (16): 1280–1285. doi:10.1212/WNL.0b013e3181bd1121. PMID 19776381. S2CID 207116101.
  43. ^ Hedrich, K; Meyer, E-M; Schüle, B (2004). "Myoclonus–dystonia: Detection of novel, recurrent, and de novo SGCE mutations". Neurology. 62 (7): 1229–1231. doi:10.1212/01.WNL.0000118286.75059.35. PMID 15079037. S2CID 11657343.
  44. ^ Ethofer, T; Seeger, U; Klose, U; Erb, M; Kardatzki, B; Kraft, E; Landwehrmeyer, G B; Grodd, W; Storch, A (2004). "Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency". Neurology. 62 (6): 1016–1018. doi:10.1212/01.WNL.0000115385.45515.DF. PMID 15037717. S2CID 8287824.
  45. ^ Kassubek, Jan; Gaus, Wilhelm; Landwehrmeyer, G. Bernhard (2004). "Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis". Neurology. 62 (6): 523–524. doi:10.1212/WNL.62.3.523-a. PMID 14872054.
  46. ^ Schiefer, Johannes; Landwehrmeyer, Bernhard; Lüesse, Hans-Gerd; Sprünken, Arne; Puls, Christiane; Milkereit, Anna; Milkereit, Eva; Kosinski, Christoph M (2002). "Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease". Mov Disord. 17 (4): 748–757. doi:10.1002/mds.10229.
  47. ^ Brettschneider, Johannes; Petzold, Axel; Süßmuth, Sigurd D; Landwehrmeyer, Georg B; Ludolph, Albert C; Kassubek, Jan; Tumani, Hayrettin (2006). "Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes". Mov Disord. 21 (12): 2224–2227. doi:10.1002/mds.21124.
  48. ^ Björkqvist, Maria; Leavitt, Blair R; Nielsen, Jörgen E; Landwehrmeyer, Bernhard; Ecker, Daniel (2007). "Cocaine- and amphetamine-regulated transcript is increased in Huntington disease". Mov Disord. 22 (13): 1952–1954. doi:10.1002/mds.21447.
  49. ^ Priller, Josef; Ecker, Daniel; Landwehrmeyer, Bernhard; Craufurd, David (2008). "A Europe-wide assessment of current medication choices in Huntington's disease". Mov Disord. 23 (12): 1788–1788. doi:10.1002/mds.22188.
  50. ^ Priller Meyer, Christina; Priller Landwehrmeyer, Bernhard; Schwenke, Carsten; Doble, Adam; Orth, Michael; Ludolph, Albert C (2012). "Rate of change in early Huntington's disease: A clinicometric analysis". Mov Disord. 27 (1): 118–124. doi:10.1002/mds.23847.
  51. ^ Ferreira, Joaquim J; Rosser, Anne; Craufurd, David; Squitieri, Ferdinando; Mallard, Nicholas; Landwehrmeyer, Bernhard (2015). "Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial". Mov Disord. 30 (10): 1426–1429. doi:10.1002/mds.26308.
  52. ^ Long, Jeffrey D; Langbehn, Douglas R; Tabrizi, Sarah J; Landwehrmeyer, Bernhard G; Paulsen, Jane S; Warner, John; Sampaio, Cristina (2017). "Validation of a prognostic index for Huntington's disease". Mov Disord. 32 (2): 256–263. doi:10.1002/mds.26838.
  53. ^ Quarrell, Oliver W J; Nance, Martha A; Nopoulos, Peg; Reilmann, Ralf; Oosterloo, Mayke; Tabrizi, Sarah J; Furby, Hannah; Saft, Carsten; Roos, Raymund A C; Squitieri, Ferdinando; Landwehrmeyer, G Bernhard; Burgunder, Jean-Marc (2019). "Defining pediatric huntington disease: Time to abandon the term Juvenile Huntington Disease?". Mov Disord. 34 (4): 584–585. doi:10.1002/mds.27640.
  54. ^ Al Shweiki, Rami; Oeckl, Patrick; Pachollek, Adrian; Steinacker, Petra; Barschke, Peggy; Halbgebauer, Steffen; Anderl-Straub, Sarah; Lewerenz, Jan; Ludolph, Albert C; Landwehrmeyer, Georg Bernhard; Otto, Markus (2021). "Cerebrospinal Fluid Levels of Prodynorphin-Derived Peptides are Decreased in Huntington's Disease". Mov Disord. 36 (2): 492–497. doi:10.1002/mds.28300.
  55. ^ Fazio, Patrik; Schain, Martin; Mrzljak, Ladislav; Amini, Nahid; Nag, Sangram; Al-Tawil, Nabil; Fitzer-Attas, Cheryl J; Bronzova, Juliana; Landwehrmeyer, Bernhard; Sampaio, Cristina; Halldin, Christer; Varrone, Andrea (2017). "Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect". NeuroImage. 152: 330–339. doi:10.1002/mds.10229.
  56. ^ Wolf, Robert C; Grön, Georg; Sambataro, Fabio; Vasic, Nenad; Wolf, Nadine D; Thomann, Philipp A; Saft, Carsten; Landwehrmeyer, G Bernhard; Orth, Michael (2011). "Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease". J Cereb Blood Flow Metab. 31 (9): 1908–18. doi:10.1038/jcbfm.2011.60.
  57. ^ Gorges, Martin; Müller, Hans-Peter; Mayer, Isabella Maria Sophie; Gruppe, Gesa Sophie; Kammer, Thomas; Grön, Georg; Kassubek, Jan; Landwehrmeyer, G. Bernhard; Wolf, Robert Christian; Orth, Michael (2017). "Intact sensory-motor network structure and function in far from onset premanifest Huntington's disease". Sci Rep. 7 (43841). doi:10.1038/srep43841.
  58. ^ Otto, M; Ludolph, A C; Landwehrmeyer, B; Förstl, J; Diehl-Schmid; Neumann, M; Kretzschmar, H A; Schroeter, M; Kornhuber, J; Danek, A; FTLD consortium (2011). "Konsortium zur Erforschung der frontotemporalen Lobärdegeneration". Der Nervenarzt (in German). 82 (1002). doi:10.1007/s00115-011-3261-3.
  59. ^ Frings, Lars; Mader, Irina; Landwehrmeyer, G Bernhard; Weiller, Cornelius; Hüll, Michael; Huppertz, Hans-Jürgen (2011). "Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry". Hum Brain Mapp. 33 (7): 1526–35. doi:10.1002/hbm.21304.
  60. ^ Denk, Johannes; Oberhauser, Felix; Kornhuber, Johannes; Wiltfang, Jens; Fassbender, Klaus; Schroeter, Matthias L; Volk, Alexander E; Diehl-Schmid, Janine; Prudlo, Johannes; Danek, Adrian; Landwehrmeyer, Bernhard; Lauer, Martin; Otto, Markus; Jahn, Holger (2018). "Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls". PLoS One. 13 (5): e0197329. doi:10.1371/journal.pone.0197329.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  61. ^ Diehl-Schmid, Janine; Licata, Abigail; Goldhardt, Oliver; Förstl, Hans; Yakushew, Igor; Otto, Markus; Anderl-Straub, Sarah; Beer, Ambros; Christian Ludolph, Albert; Landwehrmeyer, Georg Bernhard; Levin, Johannes; Danek, Adrian; Fliessbach, Klaus; Spottke, Annika; Fassbender, Klaus; Lyros, Epameinondas; Prudlo, Johannes; Krause, Bernd Joachim; Volk, Alexander; Edbauer, Dieter; Schroeter, Matthias Leopold; Drzezga, Alexander; Kornhuber, Johannes; Lauer, Martin; Grimmer, Timo; FTLDc Study Group (2019). "FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations". Transl Psychiatry. 9 (9). doi:10.1038/s41398-019-0381-1.
  62. ^ Barschke, Peggy; Oeckl, Patrick; Steinacker, Petra; Shweiki, Mhd Rami Al; Weishaupt, Jochen H; Landwehrmeyer, G Bernhard; Anderl-Straub, Sarah; Weydt, Patrick; Diehl-Schmid, Janine; Danek, Adrian; Kornhuber, Johannes; Schroeter, Matthias L; Prudlo, Johannes; Jahn, Holger; Fassbender, Klaus; Lauer, Martin; van der Ende, Emma Louise; van Swieten, John Cornelis; Volk, Alexander E; Ludolph, Albert C; Otto, Markus; German FTLD consortium (2020). "Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion". J Neurol Neurosurg Psychiatry. 91 (5): 503–511. doi:10.1136/jnnp-2019-322476.
  63. ^ Münch, C; Ebstein, M; Seefried, U; Zhu, B; Stamm, S; Landwehrmeyer, G B; Ludolph, A C; Schwalenstöcker, B; Meyer, T (2002). "Alternative splicing of the 5′-sequences of the mouse EAAT2 glutamate transporter and expression in a transgenic model for amyotrophic lateral sclerosis". J Neurochem. 82 (3): 594–603. doi:10.1046/j.1471-4159.2002.01012.x.
  64. ^ Steinacker, Petra; Verde, Federico; Fang, Lubin; Feneberg, Emily; Oeckl, Patrick; Roeber, Sigrun; Anderl-Straub, Sarah; Danek, Adrian; Diehl-Schmid, Janine; Fassbender, Klaus; Fliessbach, Klaus; Foerstl, Hans; Giese, Armin; Jahn, Holger; Kassubek, Jan; Kornhuber, Johannes; Landwehrmeyer, G Bernhard (2002). "Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression". 89 (3): 239–247. doi:10.1136/jnnp-2017-317138. {{cite journal}}: Cite journal requires |journal= (help)
  65. ^ Süssmuth, Sigurd D; Uttner, Ingo; Landwehrmeyer, Bernhard; Pinkhardt, Elmar H; Brettschneider, Johannes; Petzold, Axel; Kramer, Bernd; Schulz, Jörg B; Palm, Christian; Otto, Markus; Ludolph, Albert C; Kassubek, Jan; Tumani, Hayrettin (2010). "Differential pattern of brain-specific CSF proteins tau and amyloid-beta in Parkinsonian syndromes". Mov Disord. 25 (9): 1284–8. doi:10.1002/mds.22895.
  66. ^ Maier, C; Baron, R; Tölle, T R; Binder, A; Birbaumer, N; Birklein, F; Gierthmühlen, J; Flor, H; Geber, C; Huge, V; Krumova, E K; Landwehrmeyer, G B; Magerl, W; Maihöfner, C; Richter, H; Rolke, R; Scherens, A; Schwarz, A; Sommer, C; Tronnier, V l; Üçeyler, N; Valet, M; Wasner, G; Treede, D-R (2010). "Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values". Pain. 150 (3): 439–450. doi:10.1016/j.pain.2010.05.002.
  67. ^ Rolke, R; Baron, R; Maier, C; Tölle, T R; Treede, D R; Beyer, A; Binder, A; Birbaumer, N; Birklein, F; Bötefür, I C; Braune, S; Flor, H; Huge, V; Klug, R; Landwehrmeyer, G B; Magerl, W; Maihöfner, C; Rolko, C; Schaub, C; Scherens, A; Sprenger, T; Valet, M; Wasserka, B (2006). "Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes". Pain. 123 (3): 231–243. doi:10.1016/j.pain.2006.01.041.
  68. ^ "Network of Excellence in Neural Networks". CORDIS. European Commission. Retrieved 30 April 2022.
  69. ^ "Neuroprotection and natural history in parkinson plus syndromes: a clinical trial of the efficacy and safety of riluzole in parkinson plus syndromes". CORDIS. European Commission. Retrieved 30 April 2022.
  70. ^ "Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease by SEN0014196". CORDIS. European Commission. Retrieved 30 April 2022.
  71. ^ "CHDI Foundation". CHDI Foundation. CHDI Foundation. Retrieved 30 April 2022.
  72. ^ "DOMINO-HD: Multi-Domain Lifestyle Targets for Improving ProgNOsis in Huntington's Disease" (PDF). JPND Research. JPND Research. Retrieved 30 April 2022.
  73. ^ "HEALTHE-RND: European eHealth care model for rare neurodegenerative diseases" (PDF). JPND Research. JPND Research. Retrieved 30 April 2022.
  74. ^ "History of the library". University Library of Tübingen. University of Tübingen. Retrieved 1 May 2022. ... 1972-1987: Richard Landwehrmeyer ...'
Scholia has a profile for Bernhard Landwehrmeyer (Q42047023).


Category:1960 births Category:University of Freiburg Category:University of Ulm faculty Category:Harvard Medical School Category:German neurologists Category:German neuroscientists Category:Fellows of the Royal College of Physicians Category:Huntington's disease Category:Living people

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bernhard_Landwehrmeyer&oldid=1085826069"